Currently, although combination therapy of endocrine therapy plus CDK4/6 inhibitors remains the standard first‐line treatment for patients with HR‐positive/HER2‐negative advanced breast cancer, drug resistance still needs to be addressed [3, 6]. Here, ERBB2 is linked to breast cancer.